Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.
Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, Cortese M, Sack D, Hill J, Newcomer W, et al. Santosham M, et al. Among authors: hohenboken m. N Engl J Med. 1991 Jun 20;324(25):1767-72. doi: 10.1056/NEJM199106203242503. N Engl J Med. 1991. PMID: 1903846 Free article. Clinical Trial.
Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers.
Rennels MB, Hohenboken MJ, Reisinger KS, Clements DA, Walter EB Jr, Blatter MM, Nonenmacher J, Hackell JG. Rennels MB, et al. Among authors: hohenboken mj. Pediatr Infect Dis J. 1998 Feb;17(2):164-6. doi: 10.1097/00006454-199802000-00019. Pediatr Infect Dis J. 1998. PMID: 9493818 Clinical Trial. No abstract available.
Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Chanthavanich P, Anderson E, Kerdpanich P, Bulitta M, Kanesa-Thasan N, Hohenboken M. Chanthavanich P, et al. Among authors: hohenboken m. Pediatr Infect Dis J. 2019 Jul;38(7):757-764. doi: 10.1097/INF.0000000000002345. Pediatr Infect Dis J. 2019. PMID: 31194712 Clinical Trial.
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N. Nassim C, et al. Among authors: hohenboken m. Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545. Pediatr Infect Dis J. 2012. PMID: 22418661 Clinical Trial.
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults.
Versage E, van Twuijver E, Jansen W, Theeuwes A, Sawlwin D, Hohenboken M. Versage E, et al. Among authors: hohenboken m. Vaccines (Basel). 2021 Dec 11;9(12):1468. doi: 10.3390/vaccines9121468. Vaccines (Basel). 2021. PMID: 34960214 Free PMC article.
Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A, Silas PE, Lamas MR, Aragón CF, Chiu NC, Chiu CH, Acuña TH, Castrejón Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM. Abdelnour A, et al. Among authors: hohenboken m. Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4. Vaccine. 2014. PMID: 24397906 Clinical Trial.
27 results